M4267
Mefenamic acid
COX inhibitor
Synonym(s):
2-[(2,3-Dimethylphenyl)amino]benzoic acid, N-(2,3-Xylyl)anthranilic acid
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H15NO2
CAS Number:
Molecular Weight:
241.29
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12161501
EC Number:
200-513-1
MDL number:
Quality level:
Product Name
Mefenamic acid,
Quality Level
originator
Shionogi
SMILES string
Cc1cccc(Nc2ccccc2C(O)=O)c1C
InChI
1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
InChI key
HYYBABOKPJLUIN-UHFFFAOYSA-N
Gene Information
human ... PTGS1(5742), PTGS2(5743)
Application
Mefenamic acid has been used:
- to test its hepatotoxic effect in the transgenic zebrafish cell line (LiPan)
- to test its neuroprotective functionality in zebrafish embryos/larvae
- in the preparation of mucoadhesive microparticles in hydrogel beads
An NSAID. Circumvents MRP-mediated multidrug resistance. Specifically and significantly potentiates the cytotoxicity of anthracyclines as well as teniposide, VP-16 and vincristine.
Biochem/physiol Actions
Mefenamic acid is an analgesic and anti-inflammatory drug. It acts as a cyclooxygenase (COX) enzyme inhibitor. It is hepatoxic and implicated in liver injury. Contrarily, mefenamic acid elicits neuroprotection in in vivo ischemic stroke models by inhibiting cell toxicity induced by glutamate. Mefenamic due its inhibitory effect on prostaglandin synthesis can be used in reducing edema and ache.
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Shionogi. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Mefenamic acid
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Protein-based drug transporters are expressed in Sf9 cells. Understanding the specific mechanisms of tumor cell transporters is an essential aspect of chemotherapeutic drug design.
Discover Bioactive Small Molecules for ADME/Tox
Janesh Gupta et al.
The New England journal of medicine, 368(2), 128-137 (2013-01-11)
Menorrhagia is a common problem, yet evidence to inform decisions about therapy is limited. In a pragmatic, multicenter, randomized trial, we compared the levonorgestrel-releasing intrauterine system (levonorgestrel-IUS) with usual medical treatment in women with menorrhagia who presented to their primary
S Kasichayanula et al.
Diabetes, obesity & metabolism, 15(3), 280-283 (2012-10-16)
Dapagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that decreases serum glucose by reducing renal glucose reabsorption, thereby promoting urinary glucose excretion. Dapagliflozin is primarily metabolized via the uridine diphosphate-glucuronosyltransferase (UGT)1A9 pathway to its major inactive metabolite, dapagliflozin
Howard Horng et al.
Chemical research in toxicology, 26(3), 465-476 (2013-02-14)
Mefenamic acid, (MFA), a carboxylic acid-containing nonsteroidal anti-inflammatory drug (NSAID), is metabolized into the chemically reactive conjugates MFA-1-O-acyl-glucuronide (MFA-1-O-G) and MFA-S-acyl-CoA (MFA-CoA), which are both implicated in the formation of MFA-S-acyl-glutathione (MFA-GSH) conjugates, protein-adduct formation, and thus the potential toxicity
Global Trade Item Number
| SKU | GTIN |
|---|---|
| M4267-500G | 04061833630785 |
| M4267-50G | 04061834058908 |